title: Lack of effect of anticonvulsant topiramate on methamphetamine-induced stereotypy and rewarding property in mice.
abstract: The effects of topiramate, a structurally novel anticonvulsant, on the methamphetamine (METH)-induced expression of stereotypy and conditioned place preference (CPP) in male ICR mice were investigated. After a single administration of METH (10 mg/kg, i.p.), mice showed stereotyped behaviors with a plateau level 25 min after drug challenge. Pretreatment with topiramate (1, 10, and 100 mg/kg, i.p.) 30 min prior to METH challenge had no effect on the expression frequency of stereotypy, compared with saline challenge. No differential effects of topiramate on METH-induced stereotyped behavior (that is, head-bobbing, circling, continuous sniffing, nail and/or wood-chip biting, and vigorous and compulsive grooming) were observed. In saline-challenged groups, the doses of topiramate examined did not induce any stereotyped behaviors. Although mice showed a significant CPP for METH (0.5 mg/kg, i.p.), pretreatment with subchronic topiramate did not affect the magnitude of CPP. Locomotor activity was not affected by the doses of topiramate tested. Conditioned rewarding or aversive effects of topiramate were not observed as indexed by the place preference procedure. These results suggested the lack of effect of topiramate on METH-induced stereotypy and rewarding property in mice.
authors.affiliation: Department of Pharmacology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo 663-8501, Japan.
authors.forename: Tomohiro
authors.initials: T
authors.lastname: Tatsuta
authors.forename: Nobue
authors.initials: N
authors.lastname: Kitanaka
authors.forename: Junichi
authors.initials: J
authors.lastname: Kitanaka
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Morita
authors.forename: Motohiko
authors.initials: M
authors.lastname: Takemura
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D000697:Central Nervous System Stimulants / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D003216:Conditioning, Operant / Q000187:drug effects*; D004298:Dopamine / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005632:Fructose / Q000031:analogs & derivatives* / Q000494:pharmacology; D006719:Homovanillic Acid / Q000378:metabolism; D008297:Male; D008694:Methamphetamine / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D051379:Mice; D008813:Mice, Inbred ICR; D009043:Motor Activity / Q000187:drug effects; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D012201:Reward; D013239:Stereotyped Behavior / Q000187:drug effects*; D000077236:Topiramate
chemical_list: D000927:Anticonvulsants; D000697:Central Nervous System Stimulants; D000077236:Topiramate; D005632:Fructose; D008694:Methamphetamine; D004298:Dopamine; D006719:Homovanillic Acid